Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP opened at $2.35 on Tuesday. Oramed Pharmaceuticals has a 52-week low of $1.67 and a 52-week high of $3.67. The stock has a market cap of $95.28 million, a P/E ratio of 9.02 and a beta of 1.77. The firm has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.40.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. Analysts predict that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after purchasing an additional 320,495 shares during the period. Renaissance Technologies LLC grew its position in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 10,774 shares during the last quarter. Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals during the 1st quarter worth about $68,000. Finally, XTX Topco Ltd acquired a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.